Aclaris Therapeutics, Inc. (ACRS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-122.2%

-$0.84

vs $3.80 price

Levered DCF

-$0.87

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-2.65

Distress zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-5.68×	-1.45×	-0.83×	-11.84×	-9.09×	-5.39×	-0.55×	-1.83×
P/B	3.58×	1.23×	0.47×	5.2×	4.18×	7.31×	1.12×	1.13×
P/S	47.18×	10.24×	2.35×	34.52×	122×	42.46×	18.48×	24.1×
EV / EBITDA	-5.45×	-3.23×	-0.29×	-11.65×	-12.38×	-5.6×	-0.49×	-2.6×
Gross margin	73.3%	85.1%	42.1%	59.8%	30.3%	20.8%	4.1%	32.1%
Operating margin	-975.9%	-758.2%	-311.6%	-302.0%	-1327.1%	-785.4%	-2627.3%	-1341.9%
Net margin	-829.6%	-705.5%	-283.1%	-292.1%	-1344.0%	-787.0%	-3817.2%	-1315.4%
Current ratio	5.28×	3.99×	4.16×	10.55×	8.94×	3.87×	3.74×	6.56×
Debt / equity	0.02×	0×	0×	0×	0×	0.3×	0.01×	0.14×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-63.0%	-84.9%	-56.3%	-44.0%	-46.0%	-135.5%	-230.8%	-61.7%
Return on invested capital	-57.7%	-75.2%	-58.1%	-38.5%	-39.2%	-89.8%	-145.2%	-54.5%
Return on assets	-40.5%	-59.9%	-44.8%	-34.1%	-36.2%	-72.1%	-164.1%	-48.2%
Free cash flow yield	-12.8%	-10.5%	-108.6%	-6.6%	-6.4%	-14.2%	-125.6%	-42.0%
Earnings yield	-17.6%	-68.9%	-120.7%	-8.5%	-11.0%	-18.5%	-206.6%	-54.6%
Enterprise value	$351.4M	$167.1M	$33.8M	$982.5M	$798.2M	$264.4M	$44.6M	$216.7M
Net debt / EBITDA	0.28×	0.48×	0.34×	0.53×	0.41×	0.23×	0.37×	0.32×
Cash conversion cycle (days)	-2,037	-607	-176	-310	-740	-330	-832	-560